Corvus Pharmaceuticals Inc (NAS:CRVS)

$ 1.84 0.05 (2.81%) Market Cap: 114.47 Mil Enterprise Value: 90.25 Mil PE Ratio: 0 PB Ratio: 2.69 GF Score: 42/100

Q1 2024 Corvus Pharmaceuticals Inc Earnings Call Transcript
May 06, 2024

$1.91 (-0.52%)

Earnings
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call Transcript
Mar 19, 2024

$1.96 (+3.16%)

Earnings
Q3 2023 Corvus Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2023

$1.58 (+6.76%)

Earnings
Corvus Pharmaceuticals Inc Soquelitinib Phase 3 Clinical Trial Plan and Business Update Conference Call Transcript
Sep 07, 2023
Q2 2023 Corvus Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$2.14 (+2.39%)

Earnings
Corvus Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 15, 2023
Corvus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Corvus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2023

$1.3 (+8.33%)

Earnings
Q4 2022 Corvus Pharmaceuticals Inc Earnings Call Transcript
Mar 28, 2023

$0.6481 (-0.29%)

Earnings
Corvus Pharmaceuticals Inc R&D Corporate Call Transcript
Dec 12, 2022
Q3 2022 Corvus Pharmaceuticals Inc Earnings Call Transcript
Nov 03, 2022

$0.864 (+0.01%)

Earnings
Q2 2022 Corvus Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2022

$0.96 (+4.80%)

Earnings
Corvus Pharmaceuticals Inc R&D Symposium Transcript
May 10, 2022
Q4 2021 Corvus Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2022

$1.59 (-3.64%)

Earnings
Corvus Pharmaceuticals Inc Update on Mupadolimab and Other Topics - Call Transcript
Nov 12, 2021
Corvus Pharmaceuticals Inc Phase 3 Anti-CD73 Update Call Transcript
Jul 15, 2021
Corvus Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 15, 2021
Corvus Pharmaceuticals, Inc. - Special Call Transcript
Feb 04, 2021
Corvus Pharmaceuticals, Inc. - Special Call Transcript
Nov 12, 2020
Q2 2020 Corvus Pharmaceuticals Inc Earnings Call Transcript
Jul 30, 2020

$4.27 (+2.64%)

Earnings
Corvus Pharmaceuticals, Inc. - Special Call Transcript
Jul 07, 2020
Corvus Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 09, 2020
Q1 2020 Corvus Pharmaceuticals Inc Earnings Call Transcript
Apr 30, 2020

$2.43 (-3.95%)

Earnings
Q4 2019 Corvus Pharmaceuticals Inc Earnings Call Transcript
Mar 05, 2020

$3.6 (-6.87%)

Earnings
Corvus Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019
Corvus Pharmaceuticals, Inc. - Special Call Transcript
Nov 08, 2019
Q3 2019 Corvus Pharmaceuticals Inc Earnings Call Transcript
Oct 29, 2019

$3.54 (-3.28%)

Earnings
Q2 2019 Corvus Pharmaceuticals Inc Earnings Call Transcript
Aug 01, 2019

$3.83 (-2.05%)

Earnings
Corvus Pharmaceuticals Inc ASCO Investor and Analyst Reception Transcript
Jun 02, 2019
Q1 2019 Corvus Pharmaceuticals Inc Earnings Call Transcript
May 09, 2019

$4.11 (+1.48%)

Earnings

Corvus Pharmaceuticals Inc Phase 3 Anti-CD73 Update Call Transcript

Jul 15, 2021 / 08:30PM GMT

Release Date Price: $2.33 (-1.69%)

Transcript 8-K

Operator

Greetings. Welcome to the Corvus Pharmaceuticals conference call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the conference over to your host, Zack Kubow of Real Chemistry. Thank you. You may begin.

Zack Kubow

Thank you, operator, and good afternoon, everyone. Thank you for joining us for the Corvus Pharmaceuticals conference call to discuss an update on mupadolimab and other topics. Joining me on the call from the company are Dr. Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; and Dr. Mehrdad Mobasher, Chief Medical Officer. The executive team will open the call with some prepared remarks followed by a question-and-answer period.

I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.